Skip to Content
Merck
  • Lights and shadows of the actual European guidelines on bioanalytical method validation: the case of raltegravir.

Lights and shadows of the actual European guidelines on bioanalytical method validation: the case of raltegravir.

Therapeutic drug monitoring (2014-04-18)
Sara Baldelli, Dario Cattaneo, Serena Fucile, Emilio Clementi
ABSTRACT

Recently, the European Medicines Agency (EMA) has released new guidelines on the validation of bioanalytical methods. In this work, we compared the analytical performance of 2 high-performance liquid chromatography with tandem mass spectrometry methods designed for the quantification of the antiretroviral drug raltegravir (RAL) that fully accomplish the criteria according to the new EMA guidelines. The first method was developed with the goal of separating RAL from its main metabolite, whereas in the second method, we deliberately did not discriminate the parent drug from its metabolite. After validation, both methods were used for the quantification of plasma samples from HIV-infected patients on RAL-based maintenance antiretroviral therapy. Incurred reanalysis of samples obtained from patients receiving RAL as therapy evidenced optimal performance for both methods. Similarly, the comparison of both methods performed by the Deming test showed that they correlate significantly with each other (Pearson coefficient of regression 0.97, P < 0.0001) with no significant deviation from linearity according to the Cusum test. The Bland-Altman test, however, showed a mean difference between the 2 methods of 54.1% (limits of agreements of ±1.96 SD ranged from -163.3% to +271.5%). Such differences were significantly affected by interindividual variations in the production of RAL metabolites. We conclude that the recently released EMA guidelines on bioanalytical method validation present some limitations related to the process of method development. To have confidence in the drug-concentration measurements, laboratories must demonstrate their performance through the participation in international proficiency testing schemes that must include patient samples.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methanol, BioReagent, ≥99.93%
Sigma-Aldrich
Ammonium acetate, ≥99.99% trace metals basis
Sigma-Aldrich
Methanol, ACS reagent, ≥99.8%
Sigma-Aldrich
Methanol, HPLC Plus, ≥99.9%
Sigma-Aldrich
Methanol, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
Methanol, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Methanol, NMR reference standard
Supelco
Methanol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ammonium acetate, BioXtra, ≥98%
Sigma-Aldrich
Ammonium acetate solution, for molecular biology, 7.5 M
Supelco
Methanol, analytical standard
Sigma-Aldrich
Ammonium acetate solution, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Ammonium acetate, BioUltra, for molecular biology, ≥99.0%
Sigma-Aldrich
Methanol, anhydrous, 99.8%
Sigma-Aldrich
Ammonium acetate, 99.999% trace metals basis
Sigma-Aldrich
6,7-Dimethyl-2,3-di(2-pyridyl)quinoxaline, 98%
Supelco
Ammonium acetate, LiChropur, eluent additive for LC-MS
Sigma-Aldrich
Methanol, Absolute - Acetone free
Sigma-Aldrich
Methanol, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
Methanol, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
Methanol, ACS reagent, ≥99.8%
Sigma-Aldrich
Methanol, ACS reagent, ≥99.8%
Sigma-Aldrich
Ammonium acetate, reagent grade, ≥98%
Sigma-Aldrich
Ammonium acetate, for molecular biology, ≥98%
Sigma-Aldrich
Ammonium acetate, ACS reagent, ≥97%
Sigma-Aldrich
Methanol-12C, 99.95 atom % 12C
Sigma-Aldrich
Potassium hydride, in paraffin
Sigma-Aldrich
Methanol solution, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 3 mm × 8 in.
Sigma-Aldrich
Potassium hydride, 30 wt % dispersion in mineral oil
Sigma-Aldrich
Potassium, chunks (in mineral oil), 98% trace metals basis